false
0001537561
0001537561
2024-09-20
2024-09-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 20, 2024
ARCH
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
000-54986 |
|
46-0524102 |
| (State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
| 235
Walnut Street, Suite 6 |
|
|
| Framingham,
Massachusetts |
|
01702 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (617) 431-2313
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| N|A |
|
N|A |
|
N|A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
As
previously disclosed in the Current Report on Form 8-K filed by Arch Therapeutics, Inc. (the “Company”) with the Securities
and Exchange Commission (“SEC”) on May 21, 2024, the Company entered into a Securities Purchase Agreement, dated May
15, 2024 (the “SPA”), with certain institutional and accredited individual investors who have previously purchased
secured promissory notes from the Company, providing for the issuance and sale by the Company to the investors certain Secured Promissory
Notes (each a “2024 First Note” and collectively, the “2024 First Notes”) convertible into shares
of common stock, par value $0.001 per share (the “Common Stock”) (the “Convertible Notes Offering”).
The initial closing (the “Initial Closing”) of the Convertible Notes Offering occurred on May 15, 2024 (the “Initial
Closing Date”).
As
previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on June 18, 2024, the Company consummated a
second closing on June 12, 2024 (the “Second Closing”) of the Convertible Notes Offering pursuant to the terms and
conditions of the SPA with a certain institutional investor providing for the issuance and sale by the Company to the investor a 2024
First Note convertible into shares of Common Stock. The 2024 First Note was issued as part of the Convertible Notes Offering previously
authorized by the Company’s board of directors. In connection with the Second Closing of the Convertible Notes Offering, the Company
issued and sold to the investor a 2024 First Note in the principal amount of $180,000, which includes a $30,000 original issue discount
in respect of the 2024 First Note. The net proceeds for the sale of the 2024 First Note was approximately $150,000, after deducting issuance
discounts. The Second Closing of the sale of the 2024 First Note under the SPA occurred on June 12, 2024.
As
previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on June 28, 2024, the Company consummated a
third closing on June 26, 2024 (the “Third Closing”) of the Convertible Notes Offering pursuant to the terms and conditions
of the SPA with a certain institutional investor providing for the issuance and sale by the Company to the investor a 2024 First Note
convertible into shares of Common Stock. The 2024 First Note was issued as part of the Convertible Notes Offering previously authorized
by the Company’s board of directors. In connection with the Third Closing of the Convertible Notes Offering, the Company issued
and sold to the investor a 2024 First Note in the principal amount of $90,000, which includes a $15,000 original issue discount in respect
of the 2024 First Note. The net proceeds for the sale of the 2024 First Note was approximately $75,000, after deducting issuance discounts.
The Third Closing of the sale of the 2024 First Note under the SPA occurred on June 26, 2024.
As
previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on July 22, 2024, the
Company consummated a fourth closing on July 16, 2024 (the “Fourth Closing”) of the Convertible Notes Offering pursuant
to the terms and conditions of the SPA with certain institutional and accredited individual investors who have previously purchased secured
promissory notes from the Company, providing for the issuance and sale by the Company to the Investors 2024 First Notes convertible into
shares of Common Stock. The 2024 First Notes were issued as part of the Convertible Notes Offering previously authorized by the Company’s
board of directors. In connection with the Fourth Closing of the Convertible Notes Offering, the Company issued and sold to the Investors
2024 First Notes in the aggregate principal amount of $168,000, which includes an aggregate $28,000 original issue discount in respect
of the 2024 First Notes. The net proceeds for the sale of the 2024 First Notes was approximately $140,000, after deducting issuance discounts.
The Fourth Closing of the sale of the 2024 First Notes under the SPA occurred on July 16, 2024.
As
previously disclosed in the Current Report on Form 8-K filed by the Company with the SEC on August 2, 2024, the Company consummated a
fifth closing on July 29, 2024 (the “Fifth Closing”) of the Convertible Notes Offering pursuant to the terms and conditions
of the SPA with certain institutional and accredited individual investors who have previously purchased secured promissory notes from
the Company (the “Investors”), providing for the issuance and sale by the Company to the Investors 2024 First Notes
convertible into shares of Common Stock. The 2024 First Notes were issued as part of the Convertible Notes Offering previously authorized
by the Company’s board of directors. In connection with the Fifth Closing of the Convertible Notes Offering, the Company issued
and sold to the Investors 2024 First Notes in the aggregate principal amount of $96,000, which includes an aggregate $16,000 original
issue discount in respect of the 2024 First Notes. The net proceeds for the sale of the 2024 First Notes was approximately $80,000, after
deducting issuance discounts. The Fifth Closing of the sale of the 2024 First Notes under the SPA occurred on July 29, 2024 (the “Fifth
Closing Date”).
As
previously disclosed in the Current Report on Form 8-K filed by the Company on August 20, 2024, the Company consummated a sixth closing
on August 19, 2024 (the “Sixth Closing”) of the Convertible Notes Offering pursuant to the terms and conditions of
the SPA with certain institutional and accredited individual investors who have previously purchased secured promissory notes from the
Company (the “Investors”), providing for the issuance and sale by the Company to the Investors 2024 First Notes convertible
into shares of Common Stock. The 2024 First Notes were issued as part of the Convertible Notes Offering previously authorized by the
Company’s board of directors. In connection with the Sixth Closing of the Convertible Notes Offering, the Company issued and sold
to the Investors 2024 First Notes in the aggregate principal amount of $120,000, which includes an aggregate $20,000 original issue discount
in respect of the 2024 First Notes. The net proceeds for the sale of the 2024 First Notes was approximately $100,000, after deducting
issuance discounts. The Sixth Closing of the sale of the 2024 First Notes under the SPA occurred on August 19, 2024 (the “Sixth
Closing Date”).
As
previously disclosed in the Current Report on Form 8-K filed by the Company on September 13, 2024, the Company consummated a seventh
closing on September 10, 2024 (the “Seventh Closing”) of the Convertible Notes Offering pursuant to the terms and
conditions of the SPA with certain institutional and accredited individual investors who have previously purchased secured promissory
notes from the Company (the “Investors”), providing for the issuance and sale by the Company to the Investors 2024
First Notes convertible into shares of Common Stock. The 2024 First Notes were issued as part of the Convertible Notes Offering previously
authorized by the Company’s board of directors. In connection with the Seventh Closing of the Convertible Notes Offering, the Company
issued and sold to the Investors 2024 First Notes in the aggregate principal amount of $129,600, which includes an aggregate $21,600
original issue discount in respect of the 2024 First Notes. The net proceeds for the sale of the 2024 First Notes was approximately $108,000,
after deducting issuance discounts. The Seventh Closing of the sale of the 2024 First Notes under the SPA occurred on September 10, 2024
(the “Seventh Closing Date”).
On
September 20, 2024, the Company consummated an eighth closing (the “Eighth Closing”) of the Convertible Notes Offering
pursuant to the terms and conditions of the SPA with certain institutional and accredited individual investors who have previously purchased
secured promissory notes from the Company (the “Investors”), providing for the issuance and sale by the Company to
the Investors 2024 First Notes convertible into shares of Common Stock. The 2024 First Notes were issued as part of the Convertible Notes
Offering previously authorized by the Company’s board of directors. In connection with the Eighth Closing of the Convertible Notes
Offering, the Company issued and sold to the Investors 2024 First Notes in the aggregate principal amount of $129,600, which includes
an aggregate $21,600 original issue discount in respect of the 2024 First Notes. The net proceeds for the sale of the 2024 First Notes
was approximately $108,000, after deducting issuance discounts. The Eighth Closing of the sale of the 2024 First Notes under the SPA
occurred on September 20, 2024 (the “Eighth Closing Date”).
Use
of Proceeds
The
Company intends to use the net proceeds from the Convertible Notes Offering primarily for working capital and general corporate purposes,
and has not allocated specific amounts for any specific purposes.
2024
First Notes
The
2024 First Notes become due and payable on September 30, 2024 (the “Maturity Date”) and may be prepaid provided that
an Event of Default (as defined therein) has not occurred. The 2024 First Notes bear interest on the unpaid principal balance at a rate
equal to 10% (computed on the basis of the actual number of days elapsed in a 360-day year) per annum accruing from the Eighth Closing
Date until the 2024 First Notes become due and payable at maturity or upon their conversion, acceleration or by prepayment, and may become
due and payable upon the occurrence of an Event of Default under the 2024 First Notes. Any amount of principal or interest on the 2024
First Notes which is not paid when due shall bear interest at the rate of the lesser of (i) 18% per annum or (ii) the maximum amount
allowed by law from the due date thereof until payment in full (the “Default Interest”).
The
2024 First Notes issued in connection with the Eighth Closing are convertible into an aggregate of 259,200 shares of Common Stock (such
shares of Common Stock, the “Conversion Shares”) at the option of the holder of the 2024 First Notes (the “Holders”)
from the Eighth Closing Date at the Conversion Price (as defined below) through the later of (i) the Maturity Date and (ii) the date
of payment of the Default Amount (as defined in the 2024 First Notes); provided, however, the 2024 First Notes include a provision
preventing such conversion if, as a result, the Holder, together with its affiliates and any other persons whose beneficial ownership
of Company Common Stock would be aggregated with the Holder’s, would be deemed to beneficially own more than 4.99% of the outstanding
shares of the Company’s Common Stock (the “Note Ownership Limitation”) immediately after giving effect to the
Conversion; and provided further, the Holder, upon notice to the Company, may increase or decrease the Note Ownership Limitation;
provided that (i) the Note Ownership Limitation may only be increased to a maximum of 9.99% of the outstanding shares of the Company’s
Common Stock; and (ii) any increase in the Note Ownership Limitation will not become effective until the 61st day after delivery
of such waiver notice. As previously disclosed in the Current Report on Form 8-K filed by the Company
on September 19, 2024, effective September 15, 2024, among other things, the principal amount the Notes issued in connection with the
Fourth Closing, Fifth Closing, Sixth Closing and Seventh Closing, was increased by a factor of 1.03. Giving effect to the foregoing,
the 2024 First Notes issued in connection with the First Closing, Second Closing, Third Closing, Fourth Closing, Fifth Closing,
Sixth Closing, Seventh Closing and Eighth Closing have a total outstanding principal amount of $3,148,608, and are convertible into an
aggregate of 6,297,216 shares of Common Stock.
The
initial conversion price of the 2024 First Notes (the “Conversion Price”) shall be equal to $0.50 per share and may
be reduced or increased proportionately as a result of any stock dividends, recapitalizations, reorganizations, and similar transactions.
If the Company fails to deliver the shares of Common Stock issuable upon a conversion by the Deadline (as defined in the 2024 First Notes),
then the Company is obligated to pay such 2024 First Note Holders $5,000 per day in cash for each day beyond the Deadline.
The
2024 First Notes contains customary events of default, which includes, among other things, (i) the Company’s failure to pay when
due any principal or interest payment under the 2024 First Notes; (ii) the insolvency of the Company; (iii) delisting of the Company’s
Common Stock; (iv) the Company’s breach of any material covenant or other material term or condition under the 2024 First Notes;
and (v) the Company’s breach of any representations or warranties under the 2024 First Notes which cannot be cured within five
days. Further, Events of Default under the 2024 First Notes also include (i) the unavailability of Rule 144 on or after six months from
the Issue Date (as defined therein); (ii) the Company’s failure to deliver the shares of Common Stock to the 2024 First Note Holders
upon exercise by such Holder of its conversion rights under the 2024 First Notes; (iii) the Company’s loss of the “bid”
price for its Common Stock and/or a market and such loss is not cured during the specified cure periods; and (iv) the Company’s
failure to complete an uplist to a National Exchange (as defined therein) by September 30, 2024.
Upon
an Event of Default, the 2024 First Notes shall become immediately due and payable and the Company shall pay the 2024 First Note Holders
an amount equal to 125% (the “Default Premium”) multiplied by the sum of the outstanding principal amount of the 2024
First Notes plus any accrued and unpaid interest on the unpaid principal amount of the 2024 First Notes to the date of payment, plus
any Default Interest and any other amounts owed to the Holder under the SPA (the “Default Amount”); provided
that, upon any subsequent Event of Default not in connection with the first Event of Default, the Holder shall be entitled to an additional
5% to the Default Premium for each subsequent Event of Default. At the election of each 2024 First Note Holder, the Default Amount may
be paid in cash or shares of Common Stock equal to the Default Amount divided by the Conversion Price at the time of payment.
Upon
the closing of the transaction that results in the uplist of the Common Stock to a National Exchange, 100% of the then outstanding principal
amount of the 2024 First Notes shall automatically convert (the “Automatic Conversion”) into shares of Common Stock
(the “Automatic Conversion Shares”), with the conversion price for purposes of such Automatic Conversion being $0.515625
per share. Upon the Automatic Conversion and to the extent that the beneficial ownership of the Holders of 2024 First Notes would increase
over the applicable Note Ownership Limitation, the Holder will receive pre-funded warrants (the “2024 Note Conversion Pre-Funded
Warrants”, and the shares issuable upon exercise thereof, the “2024 Note Conversion Pre-Funded Warrant Shares”)
in lieu of shares of Common Stock otherwise issuable to the Holder in connection with the Automatic Conversion, which 2024 Note Conversion
Pre-Funded Warrants shall have an exercise price of $0.000125 per share, may be exercised on a cashless basis, shall be exercisable immediately
upon issuance and shall contain a customary beneficial ownership limitation provision. In addition, upon the Automatic Conversion, the
Holder shall receive a warrant (the “Uplist Conversion Warrant”, and the shares issuable upon exercise thereof, the
“Uplist Conversion Warrant Shares”) to purchase a number of shares of Common Stock equal to the number of shares of
Common Stock (or shares of Common Stock underlying 2024 Note Conversion Pre-Funded Warrants, if any) issued upon the Automatic Conversion.
The Uplist Conversion Warrant shall have an exercise price per share of $0.50 and shall otherwise be identical to the warrants (other
than pre-funded warrants) sold pursuant to the securities purchase agreement dated November 8, 2023, as amended. The Company also agreed
in the 2024 First Notes to file no later than 60 days after the closing of an uplist to a National Exchange a registration statement
on Form S-4, or other appropriate form, registering the offer by the Company to exchange, on a one-for-one basis, all outstanding Uplist
Conversion Warrants and certain other warrants for newly issued warrants identical to the warrants being sold in the offering that results
in the uplist to a National Exchange, which warrants are expected to be listed under the symbol “ARTHW.”
The
2024 First Notes issued in connection with the Fourth Closing, Fifth Closing, Sixth Closing, Seventh Closing and Eighth Closing will
be senior in priority to the 2024 First Notes previously issued in connection with the First Closing, Second Closing, and Third Closing,
and the notes previously issued pursuant to the Securities Purchase Agreement, dated as of July 6, 2022, by and among the Company and
each of the parties listed on the signature pages thereto.
Registration
Rights Agreement
On
the Initial Closing Date, the Company entered into a Registration Rights Agreement with the Investors (the “Registration Rights
Agreement”), pursuant to which the Company is obligated, subject to certain conditions, to file with the Securities and Exchange
Commission within 60 days after the Initial Closing Date one or more registration statements (any such registration statement, a “Resale
Registration Statement”) to register the Conversion Shares for resale under the Securities Act of 1933, as amended (the “Securities
Act”). The Company’s failure to satisfy certain filing and effectiveness deadlines with respect to a Resale Registration
Statement and certain other requirements set forth in the Registration Rights Agreement may subject the Company to payment of monetary
penalties.
Security
Agreement
In
connection with the issuance of the 2024 First Notes, the Company entered into a Security Agreement with the Collateral Agent (as defined
therein) on behalf of the Investors on the Initial Closing Date (the “Security Agreement”), pursuant to which the
Company and each of its subsidiaries (together with any persons who execute a joinder to the Security Agreement, the “Debtors”)
provided as collateral to the Investors a security interest in, and a lien on, substantially all of the Debtors. Upon an Event of Default
under the 2024 First Note, each Investor may exercise its rights to the collateral pursuant to the terms of the Security Agreement.
IP
Security Agreement
In
connection with the issuance of the 2024 First Notes, the Company also entered into an Intellectual Property Security Agreement with
the Collateral Agent (as defined therein) on behalf of the Investors on the Initial Closing Date (the “IP Security Agreement”),
pursuant to which the Company and each of its subsidiaries (together with any persons who execute a joinder to the Security Agreement,
the “IP Debtors”) provided as collateral to the investors a security interest in, and a lien on, substantially all
of the IP Debtors. Upon an Event of Default under the 2024 First Notes, each Investor may exercise its rights to the collateral pursuant
to the terms of the Security Agreement.
Certain
Restrictions on Activities
The
SPA contains certain restrictions on the Company’s ability to conduct subsequent sales of its equity securities and certain business
activities. In particular, subject to certain customary exemptions, from the Initial Closing Date, until 30 days after the Resale Registration
Statement goes effective, the Company shall not file any registration statement with respect to the Company’s Common Stock.
The
issuance and sale of the 2024 First Notes have not been, and will not upon issuance be, registered under the Securities Act, and the
2024 First Notes may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any
applicable state securities laws. The Securities will be issued and sold in reliance upon an exemption from registration afforded by
Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated under Securities Act based on the following facts: each of the Investors
has represented that it is an accredited investor as defined in Rule 501 promulgated under the Securities Act; that it is acquiring the
Securities for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof
in violation of applicable securities; the Company used no advertising or general solicitation in connection with the issuance and sale
of the 2024 First Notes to the Investors; and the Securities will be issued as restricted securities. This Current Report on Form 8-K
is not and shall not be deemed to be an offer to sell or the solicitation of an offer to buy the 2024 First Notes.
The
preceding descriptions of the SPA, 2024 First Notes, Registration Rights Agreement, Security Agreement and IP Security Agreement are
qualified in their entirety by reference to the copies of the Forms of Securities Purchase Agreement, 2024 First Note, Registration Rights
Agreement, Security Agreement and IP Security Agreement attached herewith as Exhibit 10.1, Exhibit 10.2, Exhibit 10.3, Exhibit 10.4,
and Exhibit 10.5 to this Current Report on Form 8-K, respectively, which are incorporated herein by reference.
Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Reference
is made to the disclosure set forth in Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated by reference
into this Item 2.03.
Item
3.02 Unregistered Sales of Equity Securities.
Reference
is made to the disclosure set forth in Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated by reference
into this Item 3.02.
Item
9.01 Financial Statements and Exhibits.
(d)
The following exhibits are being attached herewith:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
ARCH
THERAPEUTICS, INC. |
| |
|
| Dated:
September 26, 2024 |
By: |
/s/
Terrence W. Norchi, M.D. |
| |
Name: |
Terrence
W. Norchi, M.D. |
| |
Title: |
President,
Chief Executive Officer |
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Arch Therapeutics (QB) (USOTC:ARTH)
過去 株価チャート
から 11 2024 まで 12 2024
Arch Therapeutics (QB) (USOTC:ARTH)
過去 株価チャート
から 12 2023 まで 12 2024
